BrainStorm (OTC BB: BCLI) is a company that is developing stem cell technologies to provide treatments for currently incurable neurodegenerative diseases. The Company is focused on developing adult stem cells taken from the patient's own bone marrow to treat diseases such as Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease), and Spinal Cord Injury.

Cell Cure’s scientific team, headed by Prof. Reubinoff, is a leader in the race for the development of methods for directing hESCs to develop into neurons capable of integrating into the brain and producing dopamine. They have already demonstrated partial functional recovery of Parkinsonian rats following the transplantation of non-committed hESC-derived neural precursors.

Gamida Cell employs proprietary technologies for expansion of hematopoietic progenitor cells (HPC). These technologies utilize small molecules to modulate differentiation of cultured cells. The safety of the first developed technology was demonstrated in the clinic in a Phase I/II study.

Pluristem Therapeutics, Inc. (NASDAQ: PSTI; DAX: PJT) is a bio-therapeutics Company dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy products for the treatment of several severe degenerative, malignant and autoimmune disorders. The Company’s first planned product, PLX-I, targets a $3 billion annual market and is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT). Pluristem also believes its PLacental eXpanded (PLX) cells will be helpful for a variety of other indication, including as a help to patients afflicted with Peripheral Artery Disease (PAD) with critical limb ischemia (CLI).

Proneuron Biotechnologies, a Delaware company, is in advanced stages of clinical development in a number of attractive neurological markets. Proneuron is the first company to harness the power of the body’s own immune system for the treatment of debilitating central nervous system (CNS) disorders.

TheraVitae is an emerging healthcare company focused on using the patient's own cells to treat a variety of disorders, especially cardiovascular diseases.

Coronary Artery Disease (CAD) and Congestive Heart Failure (CHF) affect millions of people around the world each year. While standard treatment can help most, the rest continue to go untreated with little or no hope. VesCell uses a patient’s own adult stem cells to treat these debilitating diseases and is a viable alternative for patients who either cannot undergo or choose not to undergo the standard treatment such as Coronary Artery Bypass Grafting (CABG).